Iron Deficiency Without Anemia: The Missed Diagnosis That Explains Your Fatigue, Palpitations, and Resting Heart Rate

She has been exhausted for two years. Her resting heart rate has climbed from 64 to 82. She gets palpitations climbing stairs. She has gained no weight and makes no sense to herself. Three physicians have told her: your blood count is normal. This is probably perimenopause.

Her ferritin is 11 ng/mL.

The blood count is normal because anemia is the end stage of iron deficiency, and she has not reached it yet. But her iron stores are profoundly depleted. The diagnosis is iron deficiency without anemia, and it is one of the most commonly missed conditions in women between 35 and 55.

The iron deficiency spectrum

Iron deficiency is a spectrum, not a binary state.

Stage 1: Iron stores deplete. Ferritin falls. Hemoglobin remains normal. Symptoms begin: fatigue, reduced exercise tolerance, elevated resting heart rate, palpitations, poor temperature regulation, cognitive changes, hair changes.

Stage 2: Iron stores are exhausted. Transferrin saturation falls. The serum iron falls. Hemoglobin begins to decline but may still be within the normal range (termed iron-deficient erythropoiesis).

Stage 3: Iron-deficiency anemia. Hemoglobin falls below the normal threshold. This is what the CBC is designed to detect.

When a physician says “your blood count is normal,” they are typically saying: you have not yet reached Stage 3. They are not saying you do not have iron deficiency. They may not have measured ferritin. The CBC is an insensitive tool for detecting Stage 1 and Stage 2 iron deficiency. 5 / Solid

Why ferritin is the test that matters

Ferritin is the storage form of iron and reflects total body iron stores. It is the earliest abnormality in the iron deficiency spectrum.

A ferritin below 30 ng/mL in a symptomatic woman is clinically significant iron deficiency, regardless of whether the laboratory’s reference range labels it as normal. Many laboratory reference ranges for ferritin in women start at 10-12 ng/mL, derived statistically from the distribution of values in the general population, which includes a large proportion of iron-deficient women. The reference range describes what is common, not what is optimal. 5 / Solid

The functional threshold, the level below which iron deficiency symptoms reliably appear and above which symptoms consistently improve , is approximately 30-50 ng/mL across multiple therapeutic studies. At ferritin below 30, the evidence for symptomatic iron deficiency is robust. At ferritin below 15, symptoms are essentially universal.

For symptomatic women, the target after treatment is ferritin 50-100 ng/mL, not simply “within the reference range.” A ferritin of 18 ng/mL is within most laboratory reference ranges and is still producing symptoms in most women at this level.

The specific labs to request:

• Ferritin (the most sensitive single test for iron deficiency)
• Serum iron and TIBC (to calculate transferrin saturation, below 20% confirms iron deficiency is reducing iron delivery)
• Complete blood count (to confirm hemoglobin and rule out concurrent anemia)

If ferritin is low-normal and the physician says “it’s within range,” the appropriate response is: “My ferritin is 18 ng/mL. I understand it’s technically within the reference range. Can we discuss whether my symptoms are consistent with functional iron deficiency at this ferritin level, and whether a trial of iron supplementation is appropriate?”

Interpreting the iron panel: ferritin, serum iron, and transferrin saturation

Ferritin is the correct starting test, but the full picture requires understanding all three components of the iron panel, because ferritin has a critical limitation: it is an acute phase reactant.

Ferritin as an acute phase reactant. Ferritin rises in response to inflammation, infection, liver disease, and metabolic syndrome. A woman with chronic low-grade inflammation, as seen in obesity, autoimmune conditions, or active infection, may have a ferritin of 45 ng/mL that appears reassuring but is masking true tissue iron deficiency. The inflammation elevates ferritin artificially. This is why a woman with active rheumatoid arthritis or inflammatory bowel disease can have iron deficiency with a normal or even elevated ferritin. 5 / Solid

In women with inflammatory conditions, transferrin saturation becomes the more reliable indicator of functional iron status, because it reflects how much of the iron-transport protein (transferrin) is actually carrying iron, independent of the inflammatory acute phase response.

Transferrin saturation and what it reveals. Transferrin saturation is calculated from serum iron divided by TIBC (total iron-binding capacity), expressed as a percentage. Normal is approximately 20-50%. A transferrin saturation below 20% in a symptomatic woman confirms that iron delivery to tissues, including the heart and skeletal muscle, is inadequate. This is the functional measure: not how much iron is stored, but how much is actually circulating and available.

The clinical pattern matters:

• Low ferritin, normal transferrin saturation: early depletion of stores, iron delivery not yet compromised. Symptoms may be beginning; treatment is warranted if symptomatic.
• Low ferritin, low transferrin saturation (below 20%): stores are exhausted and delivery is impaired. Stage 2 iron deficiency, significant symptoms are expected. Treatment is urgent.
• Normal ferritin with low transferrin saturation: consider inflammatory suppression of ferritin interpretation. True tissue iron deficiency is likely despite the normal ferritin reading.
• Normal ferritin, normal transferrin saturation, symptoms persist: iron deficiency is less likely; consider thyroid disease, B12 deficiency, sleep apnea, or cardiac workup as alternative diagnoses.

The threshold controversy. Different clinical contexts use different ferritin cutoffs, and this creates confusion when women seek care from multiple providers. Hematology guidelines may define iron deficiency as ferritin below 15 ng/mL. Research trials in heart failure use ferritin below 100 ng/mL (or ferritin below 300 ng/mL with transferrin saturation below 20%) as the definition of clinically significant iron deficiency. The World Health Organization uses below 12 ng/mL. Functional medicine practitioners often target above 80-100 ng/mL for symptom resolution in women.

The practically useful frame: in a symptomatic woman, ferritin below 30 ng/mL is clinically actionable regardless of the reference range label. Ferritin 30-100 ng/mL with low transferrin saturation or persistent symptoms warrants a therapeutic trial and clinical judgment. These thresholds are not arbitrary — they reflect the ferritin levels at which population studies show iron-dependent enzyme function begins to recover. 4 / Promising

The cardiovascular mechanisms

Cardiac energy metabolism. Iron is essential for the function of iron-sulfur clusters in the mitochondrial electron transport chain, the machinery that produces ATP in every cell. Cardiac muscle cells have extremely high metabolic demand and are particularly sensitive to iron depletion. Iron deficiency impairs cardiac energy production, and the heart compensates with increased heart rate: delivering more contractions to produce the same cardiac output. 5 / Solid

A resting heart rate of 85-95 in a woman with iron deficiency that was 64-68 at normal iron levels is a compensatory cardiac tachycardia. It resolves with iron repletion. This is not anxiety; it is physiology.

Oxygen delivery. Even in the pre-anemia stage, tissue iron depletion reduces the efficiency of oxygen extraction and delivery by red blood cells and mitochondria. Exercising muscles (and cardiac muscle) feel the oxygen deficit before the blood count shows anemia.

Arrhythmia susceptibility. Iron deficiency appears to increase susceptibility to atrial arrhythmias. Multiple mechanisms are proposed: impaired cardiac energetics reducing the threshold for ectopic depolarization, electrolyte dysregulation (iron-deficient women often have concurrent magnesium depletion), and autonomic instability. The clinical observation, that iron-deficient women with palpitations show improvement in palpitation frequency with iron repletion , is documented in case series and small trials, though definitive randomized evidence is limited. 3 / Early

Iron deficiency, exercise capacity, and the cardiac trial evidence

The cardiovascular consequences of non-anemic iron deficiency extend beyond resting heart rate. They affect the myocardium’s capacity to generate energy under load, with measurable consequences for exercise tolerance — and this mechanism has now been tested in randomized controlled trials with clear results.

Why the iron-deficient heart cannot keep up during exercise. At rest, the cardiac demand for oxidative phosphorylation is high but manageable. During exercise, myocardial oxygen consumption increases three- to sixfold. Iron-sulfur clusters in Complexes I, II, and III of the mitochondrial electron transport chain are iron-dependent, and when iron stores are depleted these complexes cannot sustain the rate of ATP synthesis the working myocardium requires. The result is not dramatic cardiac failure — it is a subtle but measurable reduction in functional capacity: earlier fatigue at submaximal workloads, reduced peak oxygen uptake (VO2 peak), and the subjective experience of being “out of breath faster than I used to be” at activities that were previously effortless. This impairment occurs with normal hemoglobin. The oxygen-carrying capacity of the blood is intact; it is the mitochondrial machinery inside the cardiac cell that is iron-limited. 5 / Solid

Diastolic function — the heart’s ability to relax and fill between beats — is also sensitive to energy availability. Relaxation is an active, ATP-consuming process. An iron-deficient myocardium with impaired mitochondrial function relaxes more slowly, contributing to the diastolic dysfunction pattern seen in some women with iron deficiency and preserved ejection fraction. This is not structural heart disease; it is metabolic insufficiency that resolves with iron repletion.

What the FAIR-HF trial established. The FAIR-HF trial (Anker et al., published in the New England Journal of Medicine, 2009) randomized 459 patients with symptomatic heart failure and reduced ejection fraction who had iron deficiency — defined as ferritin below 100 ng/mL, or ferritin 100-299 ng/mL with transferrin saturation below 20% — to IV ferric carboxymaltose versus placebo. Critically, 50% of participants did not have anemia. Iron deficiency was the enrolled criterion, not anemia.

The results were unambiguous: IV iron improved the 6-minute walk distance by a clinically meaningful margin, improved patient-reported quality of life scores, and improved New York Heart Association functional class. The benefit was equivalent in anemic and non-anemic participants. Iron deficiency independent of anemia was the therapeutic target, and treating it produced objective functional improvement. 5 / Solid

The AFFIRM-AHF trial extended these findings. AFFIRM-AHF (Ponikowski et al., published in The Lancet, 2020) enrolled 1,108 patients hospitalized for acute heart failure with concurrent iron deficiency, again using the same iron deficiency definition that did not require anemia. Randomization to IV ferric carboxymaltose versus placebo showed a significant reduction in recurrent heart failure hospitalizations in the treatment group. The reduction in cardiovascular death did not reach statistical significance individually, though the directional trend was consistent. The trial confirmed iron deficiency as an actionable therapeutic target in heart failure management, independent of anemia status. 5 / Solid

What these trials mean for women without heart failure. These trials enrolled patients with established heart failure, not the healthy perimenopausal woman with a ferritin of 11 and a resting heart rate of 88. But the mechanism is continuous. The iron-dependent mitochondrial impairment that limits a heart failure patient’s 6-minute walk distance is the same mechanism that limits a 47-year-old woman’s ability to climb two flights of stairs without feeling her heart racing. The physiology is the same. The trials establish that iron deficiency is a legitimate cardiac target at ferritin thresholds well above what most primary care labs flag as abnormal, and that treating it with adequate iron repletion produces measurable functional recovery.

Why it is missed in women

The CBC problem. The standard complete blood count measures hemoglobin, hematocrit, MCV, and red blood cell count. It does not measure ferritin. A normal CBC does not mean iron-replete. Ferritin must be ordered separately, and it is often not ordered unless the CBC shows anemia, the physician waits for Stage 3 to order the test that would have diagnosed Stage 1. 5 / Solid

The attribution problem. In perimenopausal women, symptoms of iron deficiency, fatigue, palpitations, poor sleep, cognitive fog, exercise intolerance , overlap substantially with symptoms of hormonal transition. Both may be present simultaneously. Both require treatment. But when the presenting complaint is attributed to perimenopause, iron deficiency is not separately investigated.

The symptom normalization problem. Many women with iron deficiency have had it for years, long enough for the symptoms to be perceived as baseline. They describe themselves as “always tired” or “not an exerciser” without recognizing that a ferritin of 12 is producing what they experience as their normal.

Who is at highest risk

Women at the highest risk of iron deficiency without anemia:

• Menstruating women with heavy periods. Heavy menstrual bleeding is the most common cause of iron deficiency in reproductive-age women. Perimenopausal women often have heavier, more irregular periods before the final menstrual period. Blood loss greater than 80 mL per cycle (approximately 8+ pads or tampons fully saturated) is heavy menstrual bleeding by clinical definition.

• Women 35-55 with a pattern of dietary restriction. Plant-based diets with low heme iron, intermittent fasting patterns, or long-term caloric restriction limit dietary iron intake even before bleeding losses are considered.

• Women with GI conditions. Celiac disease, inflammatory bowel disease, and bariatric surgery all impair iron absorption. Many women have celiac disease that is undiagnosed.

• Athletes. Foot-strike hemolysis in runners, increased GI iron loss with exercise, and elevated demand from high red blood cell turnover make iron deficiency common in active women at any age.

• Post-partum women. Pregnancy depletes iron stores substantially, and post-partum women are not routinely screened for persistent iron deficiency after the initial postpartum period.

Treatment: what works and what to know

Oral iron supplementation. Ferrous sulfate 325mg (containing 65mg elemental iron) is the standard first-line treatment. A 2017 randomized trial (Moretti et al.) demonstrated that alternate-day dosing produces equivalent or better iron absorption than daily dosing with significantly fewer GI side effects, the GI side effects of daily oral iron (nausea, constipation, dark stools) are the primary reason women discontinue the supplement. 4 / Promising

Practical: take ferrous sulfate every other day, on an empty stomach or with a small amount of vitamin C (50-100mg). Avoid calcium, antacids, coffee, or tea within 2 hours. Ferrous bisglycinate (a chelated form) has better tolerability and reasonable absorption for women who cannot manage ferrous sulfate.

IV iron. Ferric carboxymaltose (Injectafer) or iron sucrose administered intravenously bypasses GI absorption and is appropriate for women with celiac disease, inflammatory bowel disease, bariatric surgery, or inability to tolerate oral iron. A single infusion can replete iron stores substantially in one to three sessions. This is underutilized for symptomatic women with documented deficiency who have had poor response to or tolerance of oral supplementation.

Recheck timeline. Ferritin should be rechecked 8-12 weeks after starting supplementation. Target: ferritin above 50 ng/mL. Expect hemoglobin to normalize first (4-6 weeks) and ferritin to normalize later (8-16 weeks at typical doses). Symptoms should begin improving before labs normalize.

Dietary iron. Heme iron (from red meat, organ meats, shellfish) is more bioavailable than non-heme iron (from legumes, fortified foods, spinach). Maximizing dietary heme iron supports supplementation but is unlikely to correct significant deficiency without supplemental iron in women with ongoing losses.

What to ask for

At any appointment where fatigue, palpitations, elevated resting heart rate, or exercise intolerance are discussed:

“I would like ferritin measured specifically, not just a CBC. I understand the CBC is normal but it does not measure iron stores.”

“If my ferritin is below 30, I want to discuss a trial of supplementation regardless of whether it falls within the reference range, given my symptoms.”

If supplementation has been recommended:

“What is the target ferritin I should aim for, and when should we recheck?”

What to do this week

If any part of this article described your experience — persistent fatigue, climbing resting heart rate, palpitations on exertion, exercise tolerance that has quietly declined — these are the concrete next steps.

Get the right labs at your next appointment. Ask specifically for ferritin (not just CBC), serum iron, TIBC, and transferrin saturation. A standard CBC will not tell you your iron status. If your physician’s office uses an online portal, you can often request labs through the portal before the appointment with a note explaining your symptoms.

Know your number before you leave. When results come back, ask for the actual ferritin value, not just “your iron is normal.” A ferritin of 18 ng/mL is within most reference ranges and is clinically significant iron deficiency in a symptomatic woman. The number matters, not the flag.

Bring the threshold question to your physician. If your ferritin falls between 10 and 50 ng/mL and you are symptomatic, ask whether a supervised trial of iron supplementation is appropriate, and what ferritin target to aim for. A trial with a ferritin recheck at 8-12 weeks is a low-risk way to determine whether iron is driving your symptoms.

Track your resting heart rate. Most wearable devices report resting heart rate trends. If you have access to this data, look for a pattern over the past 6-12 months. A sustained elevation of 8-15 bpm from your previous baseline, without a clear other cause, is a physiologically meaningful signal. Document the trend to share with your physician.

Rule out the common masquerades. Iron deficiency, thyroid disease, B12 deficiency, and sleep apnea share significant symptom overlap in women between 35 and 55. A complete workup checks all four, not just one. If iron comes back normal, the workup is not complete without TSH, B12, and consideration of sleep evaluation.

If you have already been told supplementation is appropriate, prioritize the recheck. The most common failure mode is starting iron, feeling somewhat better, and not rechecking ferritin to confirm it has reached a therapeutic level. Set a calendar reminder for 8-10 weeks from the start of supplementation to request a ferritin recheck. Symptoms improving is a good sign; ferritin above 50 ng/mL is the confirmation.

Related reading

For the complete cardiac lab panel: The Women’s Cardiac Screening Lab Panel.

For the perimenopause symptom overlap that masks iron deficiency: Perimenopause Brain Fog and the Cardiac Signal.

For the palpitation differential in perimenopausal women: Atrial Fibrillation in Women.